Gland Pharma Share Price Surges 12% To Four-Year High After Strong Q1FY27 Results
Gland Pharma shares surged 12% on Tuesday, touching a more than four-year high of ₹2,989.25 on the BSE after the pharmaceutical company reported strong financial results for the June 2026 quarter. The stock gained despite weakness in the broader market. The pharma stock reached its highest level since May 2022. Over the past four trading sessions, it has gained 17%. From its 52-week low of ₹1,575…
Gland Pharma's share price surged 12% to a four-year high of ₹2,989.25 after the pharmaceutical company reported strong Q1FY27 results. The company's profit after tax rose 47% year-on-year to ₹317 crore, while revenue from operations increased 19.6% to ₹1,800 crore. EBITDA rose 33% to ₹489 crore, and the EBITDA margin improved by 276 basis points to 27.2%.
Gland Pharma's growth was driven by strong performance in the US and EU markets, despite subdued results in other key markets. The company plans to invest over ₹2,000 crore in capital expenditure over the next five years to expand capacity, with existing facilities operating at 80-90% utilisation. Analysts expect the company's long-term outlook to remain positive due to recent agreements, including a sterile API partnership with Neuland and a CDMO partnership with a global specialty pharmaceutical company.
Brief written by urgent.news from Free Press Journal's own syndicated text. Machine-written — it may contain errors, so check the original before relying on it.
